Posted On: 08/22/2016 2:59:16 PM
Post# of 72447
Thanks Sox. I saw that buyout article earlier, but did not get around to posting it.
$14B for a single indication prostate drug and a late stage phase 3 cancer drug. Seems to me like that is a pretty good ballpark to start estimating the value on K, if/when it reaches market for one or more indications. Likely it will get to market for ovarian cancer first, but when CTIX secures a partnership and funding from the other drugs, they may be able to open up several other pathways for K in parallel with the ovarian cancer indication.
$14B for a single indication prostate drug and a late stage phase 3 cancer drug. Seems to me like that is a pretty good ballpark to start estimating the value on K, if/when it reaches market for one or more indications. Likely it will get to market for ovarian cancer first, but when CTIX secures a partnership and funding from the other drugs, they may be able to open up several other pathways for K in parallel with the ovarian cancer indication.
(0)
(0)
